ImetelChat

Is the price of GERN primarily driven by computer trading? Does GERN have sufficient volume to allow this type of machine driven trading to occur? Or does this only occur with larger stocks with much larger volume? Yahoo states that GERN has an average daily trading volume of almost 1.9 Million shar...

Fisher,

My post about your establishment of a foreign message board and making money from the same was an attempt at humor, satire-- aimed at Telo.

I have noticed Telo’s attack on Fisher. He apparently believes that establishing a FOREIGN message board is a particularly bad thing to do akin to working with the Russians to undermine our democracy. Which it is, of course. But if Fisher makes enough money on the stock who cares?

Bad faith: “Bad faith (from French mauvaise foi) is a philosophical concept used by existentialist philosophers Jean-Paul Sartre and Simone de Beauvoir to describe the phenomenon where human beings under pressure from social forces adopt false values and disown their innate freedom, hence acting ina...

My definition of a bad faith investor: You decide to buy a highly speculative small-cap biotech stock with one unapproved product knowing that this stock will create doubt, confusion and lack of confidence in investors and knowing further that such stocks are highly volatile and are subject to routi...

So…I have been attempting to add a few rational comments on the GERN SA board but to little avail. That board has now turned even more negative and seems to be dominated by one or two posters, and endless repetition. I’m not exactly sure what these people want since it appears to me they wish more f...

Fisher, Thanks for your response. To answer my original question (which classification do we wish?) from the point of view of investors and of patients we wish the classification that will lead to approval in the shortest amount of time. That much, at least, appears obvious (I think.) On a positive ...

My problem, by the way, from a layman’s point of view is these various FDA drug approval classifications tend to blend in to one another. In other words, they do not appear distinct. Perhaps it’s time for the FDA to eliminate these classifications altogether and start over; the goal being considerab...

I find the below FDA drug approval classifications a bit confusing. Here is a summary provided by the agency. So in the best of all worlds which classification should we prefer for Imet? Where, exactly, does Imet fit into this scheme? •Priority Review •Breakthrough Therapy •Accelerated Approval •Fas...

BP, You observe: “For my poker playing friends and those students of the tell (Hunt or maybe it was Sargasso this means you). Anyone count the number of times Dr. Scarlett cleared his throat during the last presentation? I did--not many. On a serious note the last update was spectacular.” Given the ...

BP,

Thanks for the clarification. What you are saying, then, is one cannot assume there have been no deaths in a clinical trial simply because no such deaths have been reported.

If deaths have occurred during the present GERN/Janssen MF trial is that a material fact that must be disclosed not only to the FDA but also to GERN shareholders? If so, when must such deaths be reported? In other words, what is considered a timely disclosure?

Fisher, Thanks for your excellent reply to my posts. You observe: “The early announcement of this presentation tells me that JnJ has plans to proceed with imetelstat based on the data they already had after the first interim review back in September 2016.” That is exactly the conclusion I reached in...

Follow-up questions: Why did Scarlett make this “regulatory submission” announcement in the first place? Why was the announcement made prior to the collection and analysis of the trial data by Janssen? Why did Janssen allow Scarlett to make this announcement at the time he made it? Assumption: no CE...

Scarlett has made clear that Janssen is presently not sharing clinical trial information with him or with anyone at GERN. That is what Scarlett is stating below, correct? Charles Duncan “Yes. So your team is involved I know to some extent but I'm wondering if your team has ongoing interaction with i...

This is what I was referring to in my previous post. Wish to become depressed and bored at the same time? Read the SA posts on GERN. See below. leviek “I would say the amount of negative posters on Geron has dominated this board more then anytime in the 6 or 8 years we've been posting. Many of the g...

Hunt, I am in agreement with your post. What I do not understand about the SA board is the constant negative spin placed on the stock and the apparent high degree of anxiety. As far as I am concerned the best news GERN shareholders have received in a long time is the AML study. I see that study as a...

BP, There are two posters I have bookmarked on SA. One is delprice who seems remarkably well-informed, and the other is Hoosier Investor. I’m hoping at some point Hoosier will present an updated valuation article on GERN. See the below links: SA comments of delprice : http://seekingalpha.com/user/10...

This fact alone makes GERN very interesting: Feb 28, 2017 Incyte’s 2016 revenues “As we saw in the previous part of this series, Incyte (INCY) reported revenues of $1.1 billion for 2016. That converts to a rise of 47.0% in 2016 compared to $753.7 million in 2015. The rise comes with increasing deman...

Fisher, Yes, I believe you are correct. I just read Tefferi's patent more closely. The two patents appear to share certain language in common, thus my confusion. Thanks for the clarification. I find these patents encouraging. What I find encouraging is that GERN, and certain medical experts like Tef...